Combined Prolonged Exposure Therapy and Paroxetine for PTSD Related to the World Trade Center Attack: A Randomized Controlled Trial
Patients with PTSD from experiences during the World Trade Center attack responded better to paroxetine, up to 50 mg/day, than placebo over 10 weeks of exposure therapy that included weekly 90-minute guided imagery sessions and cognitive-behavioral exercises. By week 10, 42% of patients in the parox...
Gespeichert in:
Veröffentlicht in: | The American journal of psychiatry 2012-01, Vol.169 (1), p.80-88 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 88 |
---|---|
container_issue | 1 |
container_start_page | 80 |
container_title | The American journal of psychiatry |
container_volume | 169 |
creator | Schneier, Franklin R. Neria, Yuval Pavlicova, Martina Hembree, Elizabeth Suh, Eun Jung Amsel, Lawrence Marshall, Randall D. |
description | Patients with PTSD from experiences during the World Trade Center attack responded better to paroxetine, up to 50 mg/day, than placebo over 10 weeks of exposure therapy that included weekly 90-minute guided imagery sessions and cognitive-behavioral exercises. By week 10, 42% of patients in the paroxetine group remitted, compared with 17% in the placebo group. The differences did not persist for patients who continued therapies beyond 10 weeks; by week 22, the remission rate was 45% for both treatments among those remaining in the study.
Objective:Selective serotonin reuptake inhibitors (SSRIs) are often recommended in combination with established cognitive-behavioral therapies (CBTs) for posttraumatic stress disorder (PTSD), but combined initial treatment of PTSD has not been studied under controlled conditions. There are also few studies of either SSRIs or CBT in treating PTSD related to terrorism. The authors compared prolonged exposure therapy (a CBT) plus paroxetine (an SSRI) with prolonged exposure plus placebo in the treatment of terrorism-related PTSD.
Method:Adult survivors of the World Trade Center attack of September 11, 2001, with PTSD were randomly assigned to 10 weeks of treatment with prolonged exposure (10 sessions) plus paroxetine (N=19) or prolonged exposure plus placebo (N=18). After week 10, patients discontinued prolonged exposure and were offered 12 additional weeks of continued randomized treatment.
Results:Patients treated with prolonged exposure plus paroxetine experienced significantly greater improvement in PTSD symptoms (incidence rate ratio=0.50, 95% CI=0.30–0.85) and remission status (odds ratio=12.6, 95% CI=1.23–129) during 10 weeks of combined treatment than patients treated with prolonged exposure plus placebo. Response rate and quality of life were also significantly more improved with combined treatment. The subset of patients who continued randomized treatment for 12 additional weeks showed no group differences.
Conclusions:Initial treatment with paroxetine plus prolonged exposure was more efficacious than prolonged exposure plus placebo for PTSD related to the World Trade Center attack. Combined treatment medication and prolonged exposure therapy deserves further study in larger samples with diverse forms of PTSD and over longer follow-up periods. |
doi_str_mv | 10.1176/appi.ajp.2011.11020321 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_916145206</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>916145206</sourcerecordid><originalsourceid>FETCH-LOGICAL-a558t-384b766f9069626f18e0ab767a580928f2c3ffe176d9c6b34117bcd9c75429e13</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi0EokvhL1SWEOKUxR-xE3NbhfIhVaIqi-AWOcmEZnHiYDtSy5U_ziy7BcSBk8czz7wzmpeQM87WnBf6hZ3nYW1381owzjHFBJOC3yMrrqTKCiHK-2TFGBOZUfLzCXkU4w6_TBbiITkR3LAyN_mK_Kj82AwTdPQyeOenLxid38w-LgHo9hqCnW-pnbBsg7-BhCjtfaCX2w-v6BU4m7AheZqugX7ywXV0G2wHtIIpQaCblGz79SXd0CsU8ePwHfHKTwmHOdjDg3WPyYPeughPju8p-fj6fFu9zS7ev3lXbS4yq1SZMlnmTaF1b5g2Wuiel8AsZgqrSmZE2YtW9j3gdTrT6kbmeKimxbhQuTDA5Sl5ftCdg_-2QEz1OMQWnLMT-CXWhmueK8E0kk__IXd-CRMuV3PGmWK5ETlS-kC1wccYoK_nMIw23CJU712q9y7V6FK9d6m-cwkbz47ySzNC97vtzhYEnh0BG1vr-mCndoh_OJUXoigEcvLA_Rr0147_Hf8Tmnmr1Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1010504924</pqid></control><display><type>article</type><title>Combined Prolonged Exposure Therapy and Paroxetine for PTSD Related to the World Trade Center Attack: A Randomized Controlled Trial</title><source>MEDLINE</source><source>American Psychiatric Publishing Journals (1997-Present)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Schneier, Franklin R. ; Neria, Yuval ; Pavlicova, Martina ; Hembree, Elizabeth ; Suh, Eun Jung ; Amsel, Lawrence ; Marshall, Randall D.</creator><creatorcontrib>Schneier, Franklin R. ; Neria, Yuval ; Pavlicova, Martina ; Hembree, Elizabeth ; Suh, Eun Jung ; Amsel, Lawrence ; Marshall, Randall D.</creatorcontrib><description>Patients with PTSD from experiences during the World Trade Center attack responded better to paroxetine, up to 50 mg/day, than placebo over 10 weeks of exposure therapy that included weekly 90-minute guided imagery sessions and cognitive-behavioral exercises. By week 10, 42% of patients in the paroxetine group remitted, compared with 17% in the placebo group. The differences did not persist for patients who continued therapies beyond 10 weeks; by week 22, the remission rate was 45% for both treatments among those remaining in the study.
Objective:Selective serotonin reuptake inhibitors (SSRIs) are often recommended in combination with established cognitive-behavioral therapies (CBTs) for posttraumatic stress disorder (PTSD), but combined initial treatment of PTSD has not been studied under controlled conditions. There are also few studies of either SSRIs or CBT in treating PTSD related to terrorism. The authors compared prolonged exposure therapy (a CBT) plus paroxetine (an SSRI) with prolonged exposure plus placebo in the treatment of terrorism-related PTSD.
Method:Adult survivors of the World Trade Center attack of September 11, 2001, with PTSD were randomly assigned to 10 weeks of treatment with prolonged exposure (10 sessions) plus paroxetine (N=19) or prolonged exposure plus placebo (N=18). After week 10, patients discontinued prolonged exposure and were offered 12 additional weeks of continued randomized treatment.
Results:Patients treated with prolonged exposure plus paroxetine experienced significantly greater improvement in PTSD symptoms (incidence rate ratio=0.50, 95% CI=0.30–0.85) and remission status (odds ratio=12.6, 95% CI=1.23–129) during 10 weeks of combined treatment than patients treated with prolonged exposure plus placebo. Response rate and quality of life were also significantly more improved with combined treatment. The subset of patients who continued randomized treatment for 12 additional weeks showed no group differences.
Conclusions:Initial treatment with paroxetine plus prolonged exposure was more efficacious than prolonged exposure plus placebo for PTSD related to the World Trade Center attack. Combined treatment medication and prolonged exposure therapy deserves further study in larger samples with diverse forms of PTSD and over longer follow-up periods.</description><identifier>ISSN: 0002-953X</identifier><identifier>EISSN: 1535-7228</identifier><identifier>DOI: 10.1176/appi.ajp.2011.11020321</identifier><identifier>PMID: 21908494</identifier><identifier>CODEN: AJPSAO</identifier><language>eng</language><publisher>Arlington, VA: American Psychiatric Publishing</publisher><subject>Adult and adolescent clinical studies ; Anxiety ; Anxiety disorders. Neuroses ; Behavior therapy. Cognitive therapy ; Biological and medical sciences ; Clinical trials ; Combined Modality Therapy ; Double-Blind Method ; Drug therapy ; Female ; Humans ; Implosive Therapy - methods ; Male ; Medical sciences ; Middle Aged ; Neuropharmacology ; New York City ; Paroxetine - therapeutic use ; Pharmacology. Drug treatments ; Post traumatic stress disorder ; Psychiatric Status Rating Scales ; Psychiatry ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Psychotropic drugs ; September 11 Terrorist Attacks - psychology ; Serotonin Uptake Inhibitors - therapeutic use ; Stress Disorders, Post-Traumatic - drug therapy ; Stress Disorders, Post-Traumatic - therapy ; Terrorism ; Treatment Outcome ; Treatments</subject><ispartof>The American journal of psychiatry, 2012-01, Vol.169 (1), p.80-88</ispartof><rights>Copyright © American Psychiatric Association 2012</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © American Psychiatric Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a558t-384b766f9069626f18e0ab767a580928f2c3ffe176d9c6b34117bcd9c75429e13</citedby><cites>FETCH-LOGICAL-a558t-384b766f9069626f18e0ab767a580928f2c3ffe176d9c6b34117bcd9c75429e13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://psychiatryonline.org/doi/epdf/10.1176/appi.ajp.2011.11020321$$EPDF$$P50$$Gappi$$H</linktopdf><linktohtml>$$Uhttps://psychiatryonline.org/doi/full/10.1176/appi.ajp.2011.11020321$$EHTML$$P50$$Gappi$$H</linktohtml><link.rule.ids>314,776,780,2842,4010,21605,21606,21607,27900,27901,27902,77536,77541</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25472772$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21908494$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schneier, Franklin R.</creatorcontrib><creatorcontrib>Neria, Yuval</creatorcontrib><creatorcontrib>Pavlicova, Martina</creatorcontrib><creatorcontrib>Hembree, Elizabeth</creatorcontrib><creatorcontrib>Suh, Eun Jung</creatorcontrib><creatorcontrib>Amsel, Lawrence</creatorcontrib><creatorcontrib>Marshall, Randall D.</creatorcontrib><title>Combined Prolonged Exposure Therapy and Paroxetine for PTSD Related to the World Trade Center Attack: A Randomized Controlled Trial</title><title>The American journal of psychiatry</title><addtitle>Am J Psychiatry</addtitle><description>Patients with PTSD from experiences during the World Trade Center attack responded better to paroxetine, up to 50 mg/day, than placebo over 10 weeks of exposure therapy that included weekly 90-minute guided imagery sessions and cognitive-behavioral exercises. By week 10, 42% of patients in the paroxetine group remitted, compared with 17% in the placebo group. The differences did not persist for patients who continued therapies beyond 10 weeks; by week 22, the remission rate was 45% for both treatments among those remaining in the study.
Objective:Selective serotonin reuptake inhibitors (SSRIs) are often recommended in combination with established cognitive-behavioral therapies (CBTs) for posttraumatic stress disorder (PTSD), but combined initial treatment of PTSD has not been studied under controlled conditions. There are also few studies of either SSRIs or CBT in treating PTSD related to terrorism. The authors compared prolonged exposure therapy (a CBT) plus paroxetine (an SSRI) with prolonged exposure plus placebo in the treatment of terrorism-related PTSD.
Method:Adult survivors of the World Trade Center attack of September 11, 2001, with PTSD were randomly assigned to 10 weeks of treatment with prolonged exposure (10 sessions) plus paroxetine (N=19) or prolonged exposure plus placebo (N=18). After week 10, patients discontinued prolonged exposure and were offered 12 additional weeks of continued randomized treatment.
Results:Patients treated with prolonged exposure plus paroxetine experienced significantly greater improvement in PTSD symptoms (incidence rate ratio=0.50, 95% CI=0.30–0.85) and remission status (odds ratio=12.6, 95% CI=1.23–129) during 10 weeks of combined treatment than patients treated with prolonged exposure plus placebo. Response rate and quality of life were also significantly more improved with combined treatment. The subset of patients who continued randomized treatment for 12 additional weeks showed no group differences.
Conclusions:Initial treatment with paroxetine plus prolonged exposure was more efficacious than prolonged exposure plus placebo for PTSD related to the World Trade Center attack. Combined treatment medication and prolonged exposure therapy deserves further study in larger samples with diverse forms of PTSD and over longer follow-up periods.</description><subject>Adult and adolescent clinical studies</subject><subject>Anxiety</subject><subject>Anxiety disorders. Neuroses</subject><subject>Behavior therapy. Cognitive therapy</subject><subject>Biological and medical sciences</subject><subject>Clinical trials</subject><subject>Combined Modality Therapy</subject><subject>Double-Blind Method</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Implosive Therapy - methods</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neuropharmacology</subject><subject>New York City</subject><subject>Paroxetine - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Post traumatic stress disorder</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychiatry</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Psychotropic drugs</subject><subject>September 11 Terrorist Attacks - psychology</subject><subject>Serotonin Uptake Inhibitors - therapeutic use</subject><subject>Stress Disorders, Post-Traumatic - drug therapy</subject><subject>Stress Disorders, Post-Traumatic - therapy</subject><subject>Terrorism</subject><subject>Treatment Outcome</subject><subject>Treatments</subject><issn>0002-953X</issn><issn>1535-7228</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1v1DAQhi0EokvhL1SWEOKUxR-xE3NbhfIhVaIqi-AWOcmEZnHiYDtSy5U_ziy7BcSBk8czz7wzmpeQM87WnBf6hZ3nYW1381owzjHFBJOC3yMrrqTKCiHK-2TFGBOZUfLzCXkU4w6_TBbiITkR3LAyN_mK_Kj82AwTdPQyeOenLxid38w-LgHo9hqCnW-pnbBsg7-BhCjtfaCX2w-v6BU4m7AheZqugX7ywXV0G2wHtIIpQaCblGz79SXd0CsU8ePwHfHKTwmHOdjDg3WPyYPeughPju8p-fj6fFu9zS7ev3lXbS4yq1SZMlnmTaF1b5g2Wuiel8AsZgqrSmZE2YtW9j3gdTrT6kbmeKimxbhQuTDA5Sl5ftCdg_-2QEz1OMQWnLMT-CXWhmueK8E0kk__IXd-CRMuV3PGmWK5ETlS-kC1wccYoK_nMIw23CJU712q9y7V6FK9d6m-cwkbz47ySzNC97vtzhYEnh0BG1vr-mCndoh_OJUXoigEcvLA_Rr0147_Hf8Tmnmr1Q</recordid><startdate>201201</startdate><enddate>201201</enddate><creator>Schneier, Franklin R.</creator><creator>Neria, Yuval</creator><creator>Pavlicova, Martina</creator><creator>Hembree, Elizabeth</creator><creator>Suh, Eun Jung</creator><creator>Amsel, Lawrence</creator><creator>Marshall, Randall D.</creator><general>American Psychiatric Publishing</general><general>American Psychiatric Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>201201</creationdate><title>Combined Prolonged Exposure Therapy and Paroxetine for PTSD Related to the World Trade Center Attack: A Randomized Controlled Trial</title><author>Schneier, Franklin R. ; Neria, Yuval ; Pavlicova, Martina ; Hembree, Elizabeth ; Suh, Eun Jung ; Amsel, Lawrence ; Marshall, Randall D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a558t-384b766f9069626f18e0ab767a580928f2c3ffe176d9c6b34117bcd9c75429e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult and adolescent clinical studies</topic><topic>Anxiety</topic><topic>Anxiety disorders. Neuroses</topic><topic>Behavior therapy. Cognitive therapy</topic><topic>Biological and medical sciences</topic><topic>Clinical trials</topic><topic>Combined Modality Therapy</topic><topic>Double-Blind Method</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Implosive Therapy - methods</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neuropharmacology</topic><topic>New York City</topic><topic>Paroxetine - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Post traumatic stress disorder</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychiatry</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Psychotropic drugs</topic><topic>September 11 Terrorist Attacks - psychology</topic><topic>Serotonin Uptake Inhibitors - therapeutic use</topic><topic>Stress Disorders, Post-Traumatic - drug therapy</topic><topic>Stress Disorders, Post-Traumatic - therapy</topic><topic>Terrorism</topic><topic>Treatment Outcome</topic><topic>Treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schneier, Franklin R.</creatorcontrib><creatorcontrib>Neria, Yuval</creatorcontrib><creatorcontrib>Pavlicova, Martina</creatorcontrib><creatorcontrib>Hembree, Elizabeth</creatorcontrib><creatorcontrib>Suh, Eun Jung</creatorcontrib><creatorcontrib>Amsel, Lawrence</creatorcontrib><creatorcontrib>Marshall, Randall D.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schneier, Franklin R.</au><au>Neria, Yuval</au><au>Pavlicova, Martina</au><au>Hembree, Elizabeth</au><au>Suh, Eun Jung</au><au>Amsel, Lawrence</au><au>Marshall, Randall D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combined Prolonged Exposure Therapy and Paroxetine for PTSD Related to the World Trade Center Attack: A Randomized Controlled Trial</atitle><jtitle>The American journal of psychiatry</jtitle><addtitle>Am J Psychiatry</addtitle><date>2012-01</date><risdate>2012</risdate><volume>169</volume><issue>1</issue><spage>80</spage><epage>88</epage><pages>80-88</pages><issn>0002-953X</issn><eissn>1535-7228</eissn><coden>AJPSAO</coden><abstract>Patients with PTSD from experiences during the World Trade Center attack responded better to paroxetine, up to 50 mg/day, than placebo over 10 weeks of exposure therapy that included weekly 90-minute guided imagery sessions and cognitive-behavioral exercises. By week 10, 42% of patients in the paroxetine group remitted, compared with 17% in the placebo group. The differences did not persist for patients who continued therapies beyond 10 weeks; by week 22, the remission rate was 45% for both treatments among those remaining in the study.
Objective:Selective serotonin reuptake inhibitors (SSRIs) are often recommended in combination with established cognitive-behavioral therapies (CBTs) for posttraumatic stress disorder (PTSD), but combined initial treatment of PTSD has not been studied under controlled conditions. There are also few studies of either SSRIs or CBT in treating PTSD related to terrorism. The authors compared prolonged exposure therapy (a CBT) plus paroxetine (an SSRI) with prolonged exposure plus placebo in the treatment of terrorism-related PTSD.
Method:Adult survivors of the World Trade Center attack of September 11, 2001, with PTSD were randomly assigned to 10 weeks of treatment with prolonged exposure (10 sessions) plus paroxetine (N=19) or prolonged exposure plus placebo (N=18). After week 10, patients discontinued prolonged exposure and were offered 12 additional weeks of continued randomized treatment.
Results:Patients treated with prolonged exposure plus paroxetine experienced significantly greater improvement in PTSD symptoms (incidence rate ratio=0.50, 95% CI=0.30–0.85) and remission status (odds ratio=12.6, 95% CI=1.23–129) during 10 weeks of combined treatment than patients treated with prolonged exposure plus placebo. Response rate and quality of life were also significantly more improved with combined treatment. The subset of patients who continued randomized treatment for 12 additional weeks showed no group differences.
Conclusions:Initial treatment with paroxetine plus prolonged exposure was more efficacious than prolonged exposure plus placebo for PTSD related to the World Trade Center attack. Combined treatment medication and prolonged exposure therapy deserves further study in larger samples with diverse forms of PTSD and over longer follow-up periods.</abstract><cop>Arlington, VA</cop><pub>American Psychiatric Publishing</pub><pmid>21908494</pmid><doi>10.1176/appi.ajp.2011.11020321</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0002-953X |
ispartof | The American journal of psychiatry, 2012-01, Vol.169 (1), p.80-88 |
issn | 0002-953X 1535-7228 |
language | eng |
recordid | cdi_proquest_miscellaneous_916145206 |
source | MEDLINE; American Psychiatric Publishing Journals (1997-Present); EZB-FREE-00999 freely available EZB journals |
subjects | Adult and adolescent clinical studies Anxiety Anxiety disorders. Neuroses Behavior therapy. Cognitive therapy Biological and medical sciences Clinical trials Combined Modality Therapy Double-Blind Method Drug therapy Female Humans Implosive Therapy - methods Male Medical sciences Middle Aged Neuropharmacology New York City Paroxetine - therapeutic use Pharmacology. Drug treatments Post traumatic stress disorder Psychiatric Status Rating Scales Psychiatry Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Psychotropic drugs September 11 Terrorist Attacks - psychology Serotonin Uptake Inhibitors - therapeutic use Stress Disorders, Post-Traumatic - drug therapy Stress Disorders, Post-Traumatic - therapy Terrorism Treatment Outcome Treatments |
title | Combined Prolonged Exposure Therapy and Paroxetine for PTSD Related to the World Trade Center Attack: A Randomized Controlled Trial |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T21%3A19%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combined%20Prolonged%20Exposure%20Therapy%20and%20Paroxetine%20for%20PTSD%20Related%20to%20the%20World%20Trade%20Center%20Attack:%20A%20Randomized%20Controlled%20Trial&rft.jtitle=The%20American%20journal%20of%20psychiatry&rft.au=Schneier,%20Franklin%20R.&rft.date=2012-01&rft.volume=169&rft.issue=1&rft.spage=80&rft.epage=88&rft.pages=80-88&rft.issn=0002-953X&rft.eissn=1535-7228&rft.coden=AJPSAO&rft_id=info:doi/10.1176/appi.ajp.2011.11020321&rft_dat=%3Cproquest_cross%3E916145206%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1010504924&rft_id=info:pmid/21908494&rfr_iscdi=true |